INTRODUCTION
Pyruvate dehydrogenase (EC 1.2.4.1) is a major regulatory enzyme located within the inner mitochondrial membrane of the cell, where it catalyses the conversion of pyruvate into acetyl-CoA. This enzymatic reaction proceeds through a series of steps operated by three main components known as (Ei) pyruvate decarboxylase, (E2) lipoyl reductase transacetylase and (E3) dihydrolipoyl dehydrogenase (Reed and Cox, 1966) . This latter component E3 is an integral part of the multienzyme a -keto acid dehydrogenase complexes (Linn et al., 1969) , where its function is to regenate oxidized lipoic acid. The natural substrate for E3 is a reduced lipoic acid moiety bound to a lysine residue on the other component enzymes of the dehydrogenase complexes. In vitro, E3 activity is measured using an artificial substrate, lipoamide, which has been converted to its active dihydrolipoamide form in a slightly alkaline solution of dithiothreithol, thus the name lipoamide dehydrogenase (LAD).
The determination of LAD activity in serum has recently been suggested to reflect liver damage in humans as increased levels of LAD correlated with hyperbilirubinemia (Pelley et al. 1976) . A genetic defect in LAD has been postulated to underlie the metabolic alterations observed in some patients with Friedreich's ataxia (Blass et al., 1976) . Reduced activity of LAD was documented in blood platelets from one patient and in serum from eighteen other patients with Friedreich's ataxia (Melancon et al., 1977) . It was hoped that the present fibroblast studies would confirm these previous investigations, suggesting that LAD deficiency is the major genetic defect underlying Friedreich's ataxia.
SUBJECTS AND METHODS
Cultured skin fibroblasts from 9 normal controls and 12 Friedreich's Ataxia (F.A.) patients were grown according to previously described methods (Melancon et al, 1972) and harvested by scraping after they reached confluency.
Lipoamide dehydrogenase activity was measured by recording the absorbance of NADH at 340 nm as in the serum assay (Pelley et al., 1976) , using a Unicam SP1800 ultraviolet spectrophotometer. The complete reaction mixture (one ml) contained 20-60 pig cell protein; NAD, 5mM; DTT, 15mM; lipoamide or lipoic acid, 5mM; glycylglycine buffer, 0.5M, pH 7.8 or Tris HC1 buffer, 0.1M; at 30°C. Specific activity of LAD was expressed in \i mole of NAD reduced per minute per mg of cell protein. Differential centrifugation in 0.25N sucrose was performed as previously described (Melancon and Nadler, 1973) . Pyruvate dehydrogenase was assayed according to Blass et al. (1972) and citrate synthetase by the method of Schulman and Blass (1971) .
RESULTS
The pH range for maximum LAD activity was between 7.4 and 7.8 in both normal and F.A. fibroblasts. The apparent Km and Vmax did not differ significantly between the two groups ( fig. 1 a & b) . The observed The distribution of LAD activity was further studied using subcellular fractions of fibroblast ultrasonicates from two normal controls, one F.A. patient and one Duchenne muscular dystrophy control (table IV) . Most of the LAD activity (62-84%) was recovered in the high speed supernatant fraction. However, the specific activity of LAD in the different fractions was equally comparable.
DISCUSSION
Our results of a normal LAD activity in cultured skin fibroblasts from F.A. patients with low serum LAD values suggest that LAD deficiency in F.A. might be (A) restricted to specific tissues, (B) due to the existence of isoenzymatic differences between tissues, (C) appear in serum and platelets as a phenomenon secondary to other metabolic alterations or (D) be restricted to a sub-population of patients with F.A.
The evidence for a defect in LAD being restricted to specific tissues is far from being established. If it were the case, one would expect F.A. patients to demonstrate various clinical symptoms and signs depending on which organ is specifically affected. This is not the case since neither we nor Blass et al. (1976) found different phenotypes associated with serum or platelet LAD deficiency. The existence of differ- Pelley et al. (1976) to follow a curve quite similar to the one we observed using skin fibroblasts lysates ( fig. la) The elevated serum LAD levels in acute liver damage and hyperbilirubinemia (Pelley et al., 1976) would suggest that serum LAD originates from liver mitochondria and that liver, serum and fibroblasts LAD is a unique enzyme. Platelet LAD could then be a different form of the enzyme found in liver, serum and fibroblasts. We have no data as to the nature of LAD in other body tissues.
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Recent experiments by one of us (Barbeau A., personal communication) indicate that taurine, calcium and pyridoxal phosphate have a regulatory effect on LAD in brain. Since we have previously found a renal conservation defect of taurine in F.A. patients (Lemieux et al., 1976) , the occurrence of reduced serum and platelets levels of LAD may well be a secondary phenomenon.
Finally, by analogy with the observation of Blass et al. (1977) , who within a group of 16 patients with spinocerebellar degeneration found reduced pyruvate dehydrogenase activity in only 8, we recognize that LAD deficiency may be restricted to a sub-population of patients with Friedreich's ataxia.
In conclusion, we have been unable to confirm the presence of a defect in lipoamide dehydrogenase activity using skin fibroblasts from 12 patients with Friedreich's ataxia, 9 of whom had low serum LAD levels.
We believe that the low serum LAD activity observed in our patients reflects the effect of other primary and genetic derangements within the cell or about the cell membranes.
